Calliditas Therapeutics AB (publ)
CALT · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $10,996 | $6,076 | $6,956 | $5,351 |
| - Cash | $797 | $810 | $974 | $787 |
| + Debt | $1,008 | $1,017 | $979 | $770 |
| Enterprise Value | $11,207 | $6,283 | $6,962 | $5,334 |
| Revenue | $560 | $295 | $452 | $295 |
| % Growth | 89.4% | -34.6% | 53.3% | – |
| Gross Profit | $506 | $281 | $429 | $280 |
| % Margin | 90.5% | 95.3% | 95.1% | 94.9% |
| EBITDA | -$29 | -$203 | $32 | -$159 |
| % Margin | -5.1% | -68.6% | 7.1% | -54% |
| Net Income | -$47 | -$246 | -$18 | -$168 |
| % Margin | -8.5% | -83.3% | -4.1% | -57.1% |
| EPS Diluted | -1.76 | -9.18 | -0.68 | -6.28 |
| % Growth | 80.8% | -1,250% | 89.2% | – |
| Operating Cash Flow | -$7 | -$198 | $23 | -$63 |
| Capital Expenditures | $0 | $0 | -$13 | $0 |
| Free Cash Flow | -$7 | -$198 | $10 | -$63 |